Peptide-Based Individualized Vaccines

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 2

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 3

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 4

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 5

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 6

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 7

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 8

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 9

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 10

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 11

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 12

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Overall Survival

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

OS and PFS (CR hepatoblastoma or not)Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 15

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 16

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 17

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 18

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Clinical Studies for Personalized Immuno-oncology Therapies

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Clinical Studies for Personalized Immuno-oncology Therapies

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Personalized neoantigen peptide vaccine trial at DFCI and Neon Therapeutics

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Personalized RNA vaccine trial by TRON/BioNTech

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Peptide vaccine development

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Slide 24

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Personalized Peptide Vaccines from Identification of Neoantigens to their Dosing to Patients

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators

Conclusions/Take-Away

Presented By Tetsuya Nakatsura at 2019 ASCO Breakthrough: A Global Summit for Oncology Innovators